SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 12/09/2024 at 20:06, 1 year 3 months ago

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes

Multiple Myeloma Sarclisa ASH MRD Negativity Clinical Benefit
BRIEF

published on 12/07/2024 at 17:35, 1 year 3 months ago

Rilzabrutinib: Promising Advances in the Treatment of IPT

Security Efficiency Phase III Rilzabrutinib TPI
PRESS RELEASE

published on 12/07/2024 at 17:30, 1 year 3 months ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted

Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF

published on 12/06/2024 at 07:35, 1 year 3 months ago

Sanofi Publishes Revised Financial Statements Excluding Opella

Financial Statements Biopharma Sanofi 2024 Results Opella
PRESS RELEASE

published on 12/06/2024 at 07:30, 1 year 3 months ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025

Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 5 months ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
BRIEF

published on 10/24/2024 at 14:05, 1 year 5 months ago

Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Dupixent Chronic Spontaneous Urticaria Phase 3 Data ACAAI Presentation Treatment Innovation
PRESS RELEASE

published on 10/24/2024 at 14:00, 1 year 5 months ago

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent phase 3 data in chronic spontaneous urticaria presented at ACAAI shows reduced itch and hive activity, potential new treatment for CSU patients

Dupixent Chronic Spontaneous Urticaria ACAAI Phase 3 Data Targeted Treatment
BRIEF

published on 10/21/2024 at 07:35, 1 year 5 months ago

Sanofi and CD&R join forces to grow Opella

Financial Transaction Sanofi CD&R Opella Consumer Health
PRESS RELEASE

published on 10/21/2024 at 07:30, 1 year 5 months ago

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare as Sanofi transfers a 50% stake in Opella. Opella to become a standalone leader backed by Sanofi's strategic support and guidance

Partnership Sanofi CD&R Consumer Healthcare Opella

Published on 03/26/2026 at 23:00, 2 hours ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 2 hours 55 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 3 hours ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 3 hours ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 4 hours ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 4 hours 12 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 5 hours 40 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 5 hours 47 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 5 hours 51 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:57, 6 hours 3 minutes ago

DSH-Director/PDMR Shareholding

View all EQS

Published on 03/26/2026 at 18:17, 6 hours 43 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 17:45, 7 hours 15 minutes ago

Cegedim: profitability continues to improve
Published on 03/26/2026 at 08:57, 16 hours 3 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 17 hours 30 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 1 day 6 hours ago

LNA SANTE : 2025 Annual Results

View all LES ECHOS COMFI WIRE

News